Reliure de : Joannis Francisci Pici Mirandulae,... Liber de providentia Dei contra philosophastros. - ("A la fin" :) Anno a partu Virginis M.D.VIII, no. novembris, in suburbio Novi... librum hunc... Benedictus Dulcibellus Mangius Carpensis exscripsit, stamneis usus calamis...

Numérisation partielle de reliure

Reliure de : Il magno palazzo del cardinale di Trento, poema in ottava rima di Andrea Matthioli

Numérisation partielle de reliure

Joannis Joviani Pontani Opera omnia, soluta oratione composita Nomina librorum qui in hisse tribus partibus continentur, à tergo hujus paginae notatae reperiuntur

Comprend : Centum Ptolemaei Sententiae ad Syrum fratrem a Pontano è graeco in latinum tralatae, atque expositae

Joannis Joviani Pontani Opera omnia, soluta oratione composita Nomina librorum qui in hisse tribus partibus continentur, à tergo hujus paginae notatae reperiuntur

Comprend : Centum Ptolemaei Sententiae ad Syrum fratrem a Pontano è graeco in latinum tralatae, atque expositae

[Illustrations de La Cena de le Ceneri] / [Non identifié] ; Giordano Bruno, aut. du texte

Comprend : [ Bandeau et lettre historiée p. 1. Début du Dialogue Premier. Cerfs et aigle dans le bandeau. Figure d'homme tenant un calamme et un encrier, dans le lettre. XVIè siècle.] [ Cote : BNF B 35646. ] ; [ Planche p. 56. Astronomie. Figure de la terre et tracés géométriques illustrant le Dialogue Trois. XVIè siècle.] [ Cote : BNF B 35647. ] ; [ Planche p. 58. Astronomie. Figure de la Terre et du Soleil illustrant le Dialogue Trois. XVIè siècle.] [ Cote : BNF B 35648. ] ; [ Planche p. 60. Astronomie. Figure de la terre illustrant le Dialogue Trois. XVIè siècle.] [ Cote : BNF B 35649. ] ; [ Planche p. 62. Astronomie. Figure géométrique illustrant le Dialogue Trois. XVIè siècle.] [ Cote : BNF B 35650. ] ; [ Planche p. 75. Astronomie. Figure géométrique illustrant le Dialogue Trois. XVIè siècle.] [ Cote : BNF B 35651. ] ; [ Figure p. 79 illustrant le Dialogue Trois. Navire en mer, vents. XVIè siècle.] [ Cote : BNF B 35652. ] ; [ Planche p. 98. Astronomie. Figure géométrique illustrant le Dialogue Quatre. XVIè siècle.] Ptolemaeus copernicus. [ Cote : BNF B 35653. ] ; [ Planche p. 104. Astronomie. Figure géométrique illustrant le Dialogue Cinq. XVIè siècle.] [ Cote : BNF B 35654. ] ; [ Planche p. 125. Astronomie. Figure géométrique illustrant le Dialogue Cinq. XVIè siècle.] [ Cote : BNF B 35655. ]

Integer filling facfor phases and isospin in vertical diatomic artificial molecules

Integer filling factor phases of many-electron vertically coupled diatomic artificial quantum dot molecules are investigated for different values of the interdot coupling. The experimental results are analyzed within local-spin density functional theory for which we have determined a simple lateral confining potential law that can be scaled for the different coupling regimes, and Hartree-Fock theory. Maximum density droplets composed of electrons in both bonding and antibonding or just bonding states are revealed, and interesting isospin-flip physics appears for weak interdot coupling when the systematic depopulation of antibonding states leads to changes in isospin.

Freezing of 4He and its liquid-solid interface from density functional theory

We show that, at high densities, fully variational solutions of solidlike types can be obtained from a density functional formalism originally designed for liquid 4He . Motivated by this finding, we propose an extension of the method that accurately describes the solid phase and the freezing transition of liquid 4He at zero temperature. The density profile of the interface between liquid and the (0001) surface of the 4He crystal is also investigated, and its surface energy evaluated. The interfacial tension is found to be in semiquantitative agreement with experiments and with other microscopic calculations. This opens the possibility to use unbiased density functional (DF) methods to study highly nonhomogeneous systems, like 4He interacting with strongly attractive impurities and/or substrates, or the nucleation of the solid phase in the metastable liquid.

Condensation of helium in nanoscopic alkali wedges at zero temperature

We present a complete calculation of the structure of liquid 4He confined to a concave nanoscopic wedge, as a function of the opening angle of the walls. This is achieved within a finite-range density functional formalism. The results here presented, restricted to alkali metal substrates, illustrate the change in meniscus shape from rather broad to narrow wedges on weak and strong alkali adsorbers, and we relate this change to the wetting behavior of helium on the corresponding planar substrate. As the wedge angle is varied, we find a sequence of stable states that, in the case of cesium, undergo one filling and one emptying transition at large and small openings, respectively. A computationally unambiguous criterion to determine the contact angle of 4He on cesium is also proposed.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

BACKGROUND: Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up. METHODS: BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other. Randomisation was done with permuted blocks, and stratified according to the two-arm or four-arm randomisation option, participating institution, and chemotherapy use. Patients, investigators, data managers, and medical reviewers were masked. The primary efficacy endpoint was disease-free survival (events were invasive breast cancer relapse, second primaries [contralateral breast and non-breast], or death without previous cancer event). Secondary endpoints were overall survival, distant recurrence-free interval (DRFI), and breast cancer-free interval (BCFI). The monotherapy comparison included patients randomly assigned to tamoxifen or letrozole for 5 years. In 2005, after a significant disease-free survival benefit was reported for letrozole as compared with tamoxifen, a protocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen alone; Cox models and Kaplan-Meier estimates with inverse probability of censoring weighting (IPCW) are used to account for selective crossover to letrozole of patients (n=619) in the tamoxifen arm. Comparison of sequential treatments to letrozole monotherapy included patients enrolled and randomly assigned to letrozole for 5 years, letrozole for 2 years followed by tamoxifen for 3 years, or tamoxifen for 2 years followed by letrozole for 3 years. Treatment has ended for all patients and detailed safety results for adverse events that occurred during the 5 years of treatment have been reported elsewhere. Follow-up is continuing for those enrolled in the four-arm option. BIG 1-98 is registered at clinicaltrials.govNCT00004205. FINDINGS: 8010 patients were included in the trial, with a median follow-up of 8·1 years (range 0-12·4). 2459 were randomly assigned to monotherapy with tamoxifen for 5 years and 2463 to monotherapy with letrozole for 5 years. In the four-arm option of the trial, 1546 were randomly assigned to letrozole for 5 years, 1548 to tamoxifen for 5 years, 1540 to letrozole for 2 years followed by tamoxifen for 3 years, and 1548 to tamoxifen for 2 years followed by letrozole for 3 years. At a median follow-up of 8·7 years from randomisation (range 0-12·4), letrozole monotherapy was significantly better than tamoxifen, whether by IPCW or intention-to-treat analysis (IPCW disease-free survival HR 0·82 [95% CI 0·74-0·92], overall survival HR 0·79 [0·69-0·90], DRFI HR 0·79 [0·68-0·92], BCFI HR 0·80 [0·70-0·92]; intention-to-treat disease-free survival HR 0·86 [0·78-0·96], overall survival HR 0·87 [0·77-0·999], DRFI HR 0·86 [0·74-0·998], BCFI HR 0·86 [0·76-0·98]). At a median follow-up of 8·0 years from randomisation (range 0-11·2) for the comparison of the sequential groups with letrozole monotherapy, there were no statistically significant differences in any of the four endpoints for either sequence. 8-year intention-to-treat estimates (each with SE ≤1·1%) for letrozole monotherapy, letrozole followed by tamoxifen, and tamoxifen followed by letrozole were 78·6%, 77·8%, 77·3% for disease-free survival; 87·5%, 87·7%, 85·9% for overall survival; 89·9%, 88·7%, 88·1% for DRFI; and 86·1%, 85·3%, 84·3% for BCFI. INTERPRETATION: For postmenopausal women with endocrine-responsive early breast cancer, a reduction in breast cancer recurrence and mortality is obtained by letrozole monotherapy when compared with tamoxifen montherapy. Sequential treatments involving tamoxifen and letrozole do not improve outcome compared with letrozole monotherapy, but might be useful strategies when considering an individual patient's risk of recurrence and treatment tolerability. FUNDING: Novartis, United States National Cancer Institute, International Breast Cancer Study Group.